HIMSS names Davies Award winners

HIMSS has named both the University of Iowa Hospital and Clinics (UIHC) and Lakeland HealthCare of St. Joseph’s, Mich., as 2014 Enterprise Davies Award recipients.

Given out since 2004, the award recognizes “outstanding achievement” of organizations that have utilized health IT to improve patient outcomes while achieving a return on investment, according to the organization.

Lakeland HealthCare, a not-for-profit, community-owned system of care serving a tri-county region in southwest Michigan, has three hospitals, about 30 ambulatory clinics and offers long-term, home care and hospice services. It succeeded in its “big bang implementation” of an EHR system across its acute and ambulatory care settings in 2012 using a “speed to value approach,” according to HIMSS.

Lakeland standardized care by using evidence-based guidelines, and collaboratively developed key performance indicators and a quality-focused, team-oriented culture. As a result, it significantly cut adverse events, hospital-acquired infections and improved population health outcomes, and its improvement initiatives generated nearly $22 million in savings over two years.

UIHC realized a broad range of significant benefits through health IT, including reducing instances of venous thrombosis, sepsis, pneumonia and other clinical conditions. Also, as a result of improved documentation and secondary diagnosis capture, cost avoidance associated with improved clinical outcomes and reduced mortality and length of stay, and incentives paid for quality improvements, UIHC had a net cash flow of more than $50 million from July 2013 to June 2014.

Both will be recognized at the 2014 Annual HIMSS Conference & Exhibition in Chicago next April. 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.